First Trust NYSE Arca Biotechnology ETFTSX:FBT
- LAST PRICE24.74
- TODAY'S CHANGE (%)0.27 (1.10%)
- Bid / Lots24.58/ 1
- Ask / Lots24.75/ 1
- Open / Previous Close24.74 / 24.47
- Day Range
- 52 Week Range
- Volume9,700
- Overall Morningstar RatingNot Ratedout of funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBT |
|---|
| US Equity | 93.8% |
|---|---|
| Int'l Equity | 6.1% |
| Cash | 0.1% |
| CDN Equity | 0 |
| Fixed Income | 0 |
| Other | 0 |
| Healthcare | 99.9% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 93.9% |
|---|---|
| Latin America | 0 |
| Africa | 0 |
| Asia/Oceania | 0 |
| Canada | 0 |
| Europe | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
First Trust NYSE Arca Biotech ETF | Long | 100.0% | 0.00% | $1.8M |
Reports
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | Not Rated |
| 3 Year Rating | Not Rated |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | --- |
|---|---|
Category | Sector Equity |
Sponsor | First Trust Advisors L.P. |
Inception | October 29, 2014 |
The fund will seek to replicate, to the extent possible, the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE Arca Biotechnology IndexSM. The NYSE Arca Biotechnology IndexSM is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
| Total Net Assets | $1.8M |
|---|---|
| Shares Out. | 70.0K |
| Net Asset Value (NAV) | $24.65 |
| Prem/Discount to NAV | 0.38% |
| P/E Ratio | 24.4 |
| Dividend Yield | --- |
| Dividend per Share | --- |
| Ex-Dividend Date | --- |
| Dividend Payment Date | --- |
| Beta | --- |
| Morningstar Investment Style | Sector Equity |
| Equity Style | Mid Cap Growth |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.15% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.73% |